v3.26.1
Segment Reporting
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting

Note 12. Segment Reporting

The Company has one reportable segment, which is the business of extending healthy human life by targeting molecular causes of aging.

The Company’s CODM is its chief executive officer. When evaluating the Company's financial performance, the CODM reviews total operating expenses and expense by function to make decisions on a company-wide basis.

As a single reportable segment entity, the determined measure of profit or loss is the Company’s consolidated net income (loss). Consolidated asset information for the Company’s single reportable segment is presented in the Company’s condensed consolidated balance sheets.

The table below is a summary of the segment net loss, including significant segment expenses:

 

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Collaboration revenue

 

$

2,451

 

 

$

2,412

 

 

$

5,223

 

 

$

3,863

 

Segment expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Direct program costs

 

 

16,678

 

 

 

13,955

 

 

 

29,819

 

 

 

18,584

 

Indirect research and development expenses

 

 

7,687

 

 

 

5,889

 

 

 

14,956

 

 

 

12,369

 

General and administrative

 

 

7,419

 

 

 

7,339

 

 

 

15,156

 

 

 

14,127

 

Total operating and segment expenses

 

$

(31,784

)

 

$

(27,183

)

 

$

(59,931

)

 

$

(45,080

)

Loss from operations

 

 

(29,333

)

 

 

(24,771

)

 

 

(54,708

)

 

 

(41,217

)

Total other income (expense), net

 

 

3,236

 

 

 

3,208

 

 

 

6,358

 

 

 

6,726

 

Segment and consolidated net loss

 

$

(26,097

)

 

$

(21,563

)

 

$

(48,350

)

 

$

(34,491

)